Enhertu Fam-trastuzumab Deruxtecan-nxki (T-DXd) 100mg Vial | Daiichi Sankyo China | GLT
Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.
- We reply within 24 hours with pricing, availability & COA
- Serves individuals and institutions worldwide
Prefer email? [email protected] · +86 15234153837
Generic Information: Enhertu (fam-trastuzumab deruxtecan-nxki) — China-Mainland Version
Enhertu is the originator brand of fam-trastuzumab deruxtecan-nxki, a HER2-directed antibody-drug conjugate (ADC) co-developed by Daiichi Sankyo and AstraZeneca. The molecule links a humanised anti-HER2 monoclonal antibody to a topoisomerase I inhibitor payload (deruxtecan) through a stable, cleavable tetrapeptide-based linker. The China-Mainland version is supplied as a 100 mg single-dose vial of lyophilised powder for reconstitution and intravenous infusion, manufactured by Daiichi Sankyo.
What Is Enhertu Used For?
Enhertu is indicated for adults with several HER2-expressing cancers. In the China label it is approved for HER2-positive metastatic breast cancer, HER2-low metastatic breast cancer, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma, and HER2-mutant non-small cell lung cancer. The medicine has also received an indication in China as a tumour-agnostic therapy for HER2-expressing (IHC 3+) solid tumours, making it one of the broadest HER2-directed ADCs available. Treatment is guided by a validated HER2 test.
How Does Enhertu Work?
Enhertu binds to the HER2 receptor on the surface of tumour cells and is internalised. Inside the cell, the cleavable linker releases the topoisomerase I inhibitor deruxtecan, which blocks DNA replication and triggers tumour-cell death. Because the linker is engineered for a high drug-to-antibody ratio and the released payload can cross cell membranes, Enhertu also damages neighbouring tumour cells through a bystander effect — even those that express little HER2.
Indications
In China, Enhertu is used for: HER2-positive breast cancer after prior anti-HER2 therapy; HER2-low metastatic breast cancer; HER2-positive gastric or gastro-oesophageal junction adenocarcinoma after prior lines of treatment; HER2-mutant non-small cell lung cancer; and, more recently, HER2-expressing (IHC 3+) advanced solid tumours. The exact approved indication depends on the patient's tumour type and treatment history.
Dosage
The recommended dose is 5.4 mg/kg given as an intravenous infusion once every three weeks until disease progression or unacceptable toxicity. Each 100 mg single-dose vial is reconstituted with sterile water for injection and further diluted before infusion. The number of vials per cycle depends on the patient's body weight.
Side Effects
Common side effects include nausea, fatigue, decreased appetite, alopecia, anaemia and low blood counts. Enhertu carries a boxed warning for interstitial lung disease (ILD)/pneumonitis, which requires monitoring for new or worsening respiratory symptoms, and for embryo-fetal toxicity. Left ventricular ejection fraction is monitored during treatment. Patients should report any new cough, shortness of breath or fever promptly.
Storage
Enhertu vials are stored refrigerated at 2°C to 8°C and protected from light until reconstitution. GLT ships through validated temperature-controlled cold-chain logistics with batch documentation and a certificate of analysis enclosed for every order.
Why Choose China-Sourced Enhertu?
Sourcing Enhertu from the China market offers a meaningful cost advantage over Western list prices. In the United States a single 100 mg vial is priced well above what the China-Mainland version costs, and GLT's China-sourced supply is typically priced roughly 40%–50% lower than the US list price. Compared with Japan and several European markets, the China-Mainland version also tends to be more affordable. GLT supplies the genuine, fully labelled Daiichi Sankyo product with verified batch documentation, cold-chain logistics and responsive support for both institutions and individual patients.
How to Order
To order Enhertu (fam-trastuzumab deruxtecan-nxki) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm stock, vial size and cold-chain delivery timelines to your country, and we support both healthcare institutions and individual patients.
FAQ
Is Enhertu the same as Kadcyla (T-DM1)? No. Both are HER2-targeted ADCs, but Enhertu carries a different payload (deruxtecan) and a different linker, and it is approved across a broader range of HER2-expressing cancers, including HER2-low breast cancer.
Does Enhertu require cold storage? Yes. It is a refrigerated biologic shipped by validated cold chain at 2°C to 8°C until reconstitution.
Is the China-Mainland version of Enhertu the same product? Yes. It is the same fam-trastuzumab deruxtecan-nxki molecule from Daiichi Sankyo, supplied in the 100 mg single-dose vial with the China-Mainland label.